The companies entered a definitive agreement to execute the acquisition in January 2024.
The acquisition will be deemed a business combination and marks a significant step for J&J in enhancing its oncology portfolio, particularly in the area of prostate cancer.
The strategic move will also strengthen the company’s capabilities in developing next-generation antibody-drug conjugates (ADCs).
Ambrx’s synthetic biology technology platform is intended for designing and developing advanced ADCs.
ContraFect files patent for antibacterial lysin-amp polypeptide constructs and compositions
Preview
Source: Pharmaceutical Technology
The technology combines the precision of monoclonal antibodies with chemotherapeutic agents, aiming to target and remove cancer cells more effectively and with fewer side effects than traditional chemotherapy.
The integration of Ambrx’s ADC technology into J&J’s portfolio presents a unique opportunity to advance the development and commercialisation of targeted oncology therapies.
J&J will gain access to the Ambrx pipeline comprising candidate therapeutics for a range of cancer indications.
J&J innovative medicine oncology global therapeutic area head Yusri Elsayed stated: “We’re pleased to welcome Ambrx’s talented scientific team and ADC platform to Johnson & Johnson.
“This significant opportunity sets the stage for advancing next-generation ADCs to deliver differentiated solid tumour therapies that improve patients’ lives.”
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.